NEW YORK (GenomeWeb News) – Cepheid announced after the close of the market on Thursday that its preliminary second-quarter earnings results are anticipated to beat consensus analyst estimates on the top and bottom lines.

For the three months ended June 30, the Sunnyvale, Calif.-based firm said that total revenues are expected to be about $96 million, which would beat Wall Street expectations of $92.2 million. It also would represent a 19 percent improvement over $81.0 million in revenues recorded in the second quarter of 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.